Los Angeles Capital Management
LENZ icon

Los Angeles Capital Management’s LENZ Therapeutics LENZ Stock Holding History

Los Angeles Capital Management’s Portfolio LENZ Stock Details LENZ Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$290 Sell
51
-33,020
-100% -$266K ﹤0.01% 2320
2026
Q1 		$303K Buy
33,071
+29,183
+751% +$410K ﹤0.01% 1022
2025
Q4 		$118K Buy
+3,888
New +$113K ﹤0.01% 1379

Other funds holding LENZ

RA Capital Management
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Alpha Wave Global
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $163M AUM 240.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Squarepoint
Squarepoint New York $90.5B AUM 33.95% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $71.2B AUM 41.74% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
7IH
72 Investment Holdings Stamford, Connecticut $50M AUM 647.58% 1-Year Est. Return

Los Angeles Capital Management's LENZ Position: Q2 2026 in Review

Los Angeles Capital Management reduced its LENZ Therapeutics (LENZ) stake by 100% in Q2 2026, selling an estimated $266K and leaving 51 shares worth $290. The position accounts for ﹤0.01% of the portfolio, ranked #2320.

Los Angeles Capital Management first reported a position in LENZ in Q4 2025 and has held it in 3 quarters since. The position peaked at $303K in Q1 2026. 145 funds tracked by Wall St. Rank hold LENZ as of Q2 2026.

  • Los Angeles Capital Management held 51 shares of LENZ Therapeutics worth $290 as of Q2 2026.
  • Los Angeles Capital Management sold 33,020 LENZ Therapeutics shares in Q2 2026, an estimated $266K.
  • LENZ Therapeutics made up ﹤0.01% of Los Angeles Capital Management's portfolio in Q2 2026, its #2320 holding.
  • Los Angeles Capital Management first reported a position in LENZ Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • Los Angeles Capital Management's LENZ Therapeutics position peaked at $303K in Q1 2026.
  • 145 funds tracked by Wall St. Rank held LENZ Therapeutics as of Q2 2026.

Based on Los Angeles Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.